Abstract
Objective Evaluate clinical utility and cost effectiveness of identifying pregnancies at increased risk of preterm birth using a validated proteomic biomarker risk predictor to enable proactive intervention
Study Design Pregnancies at elevated risk (≥ 15%) of preterm birth were identified in a cohort from TREETOP (NCT02787213), a study independent of biomarker development. In the screening arm, higher-risk subjects received simulated interventions based on published efficacy of multimodal treatment or care-management alone. Subjects in the non-screening arm received no interventions. Neonatal and maternal length of stay, neonatal mortality and morbidity and neonatal costs were compared between arms.
Results Multimodal/care-management modeled treatments predicted reductions in neonatal (30%/22%) and maternal (9.2%/8.5%) hospital stays, neonatal morbidity and mortality (41%/29%), and neonatal costs (34%/16%) for the screening vs. non-screening arm.
Conclusion Modeled interventions applied to pregnancies identified as higher-risk by a proteomic biomarker risk predictor demonstrate clinically and economically meaningful improvements in neonatal and maternal outcomes.
Competing Interest Statement
AF, AP, TF, GC, JB, JJB, TG and PK are stockholders and employees or contract employees of Sera Prognostics. All other authors report no conflict of interest.
Clinical Trial
NCT02787213
Funding Statement
Sponsorship (funding, study design and execution) of this work was provided by Sera Prognostics, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The following is a listing of all TREETOP (NCT02787213) IRBs. All IRBs gave approval. IRB for Human Research Medical University of South Carolina Office of Human Research Ethics The University of North Carolina at Chapel Hill Maricopa Integrated Health System IRB Oregon Health & Science University IRB University of Texas Medical Branch IRB Boston Medical Center IRB Ochsner Clinic Foundation IRB University of California, San Diego Human Research Protections Program Northwestern University IRB Indiana University IRB Duke Medicine IRB for Clinical Investigations Greenville Health System IRB Western IRB (used by Denver Health & Hospital Authority, University of Colorado-Denver, UC-Irvine, Thomas Jefferson University, Regional Obstetrical Consultants, and Baystate Medical Center).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data supporting the results presented here can be requested at data-sharing@seraprognostics.com. Data will not be made publicly available, or in any format, that may violate a subject's right to privacy. For example, dating information or identifiers that would allow data to be integrated, thereby enabling the potential identification of study subjects, are protected.
